Illumina Picked Solexa After Mulling Internal Development, Other Next-Gen Shops

Illumina CEO Flatley said the firm had "been looking quite broadly at [the next-gen sequencing] space for at least 18 months and we’ve analyzed the respective technologies that have been out on the marketplace."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.